Dennis C Sgroi
Overview
Explore the profile of Dennis C Sgroi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
8719
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mitsiades I, Onozato M, Iafrate A, Hicks D, Gulhan D, Sgroi D, et al.
Breast Cancer Res
. 2024 Dec;
26(1):185.
PMID: 39695741
Background: The HOXB13/IL17RB gene expression biomarker has been shown to predict response to adjuvant and extended endocrine therapy in patients with early-stage ER+ HER2- breast tumors. HOXB13 gene expression is...
2.
Walensky R, Baggett M, Tran K, Shepard J, Dudzinski D, Sgroi D
N Engl J Med
. 2024 Sep;
391(9):845-852.
PMID: 39231348
No abstract available.
3.
Mamounas E, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas P, et al.
Clin Cancer Res
. 2024 Feb;
30(9):1984-1991.
PMID: 38376912
Purpose: BCI (H/I) has been shown to predict extended endocrine therapy (EET) benefit. We examined BCI (H/I) for EET benefit prediction in NSABP B-42, which evaluated extended letrozole therapy (ELT)...
4.
Boyraz B, Sgroi D, Iafrate A, Lerwill M
Histopathology
. 2023 Sep;
83(6):989-993.
PMID: 37771083
Aims: Cystic hypersecretory lesions are rare and include atypical cystic hypersecretory hyperplasia (A-CHH) and cystic hypersecretory carcinoma in situ (CHC-IS). Despite detailed morphological descriptions, little is known about the genetic...
5.
Sgroi D, Treuner K, Zhang Y, Piper T, Salunga R, Ahmed I, et al.
Breast Cancer Res
. 2022 Dec;
24(1):90.
PMID: 36527133
Background: Multiple clinical trials demonstrate consistent but modest benefit of adjuvant extended endocrine therapy (EET) in HR + breast cancer patients. Predictive biomarkers to identify patients that benefit from EET...
6.
Bartlett J, Sgroi D, Treuner K, Zhang Y, Piper T, Salunga R, et al.
Clin Cancer Res
. 2022 Feb;
28(9):1871-1880.
PMID: 35144966
Purpose: The Breast Cancer Index (BCI) HOXB13/IL17BR (H/I) ratio predicts benefit from extended endocrine therapy in hormone receptor-positive (HR+) early-stage breast cancer. Here, we report the final analysis of the...
7.
Nunes R, Sella T, Treuner K, Atkinson J, Wong J, Zhang Y, et al.
Clin Cancer Res
. 2021 Aug;
27(20):5688-5696.
PMID: 34376532
Purpose: The prognostic utility of Breast Cancer Index (BCI) for risk assessment of overall (0-10 years), early (0-5 years), and late (5-10 years) distant recurrence (DR) in hormone receptor-positive (HR+)...
8.
Li K, Li T, Feng Z, Huang M, Wei L, Yan Z, et al.
Sci Adv
. 2021 Jun;
7(25).
PMID: 34144976
The link between carcinogen exposure and cancer immunogenicity is unclear. Single exposure to 12-dimethylbenz[a]anthracene (DMBA) at puberty accelerated spontaneous breast carcinogenesis in mouse mammary tumor virus-polyoma middle tumor-antigen transgenic (MMTV-PyMT...
9.
Yan C, Brunson D, Tang Q, Do D, Iftimia N, Moore J, et al.
Cell
. 2019 Apr;
177(7):1903-1914.e14.
PMID: 31031007
Xenograft cell transplantation into immunodeficient mice has become the gold standard for assessing pre-clinical efficacy of cancer drugs, yet direct visualization of single-cell phenotypes is difficult. Here, we report an...
10.
Jerevall P, Brock J, Palazzo J, Wieczorek T, Misialek M, Guidi A, et al.
Breast Cancer Res Treat
. 2018 Oct;
173(2):375-383.
PMID: 30350269
Purpose: A recent comparison of the prognostic accuracy of Breast Cancer Index (BCI) and the Recurrence Score (RS) showed that BCI was more precise than RS. BCI identified a subset...